Abstract | PURPOSE: MATERIAL AND METHODS: The outpatients selected were of both sexes, aged 40 to 80, with a chronic, stable intermittent claudication and an ankle brachial index between 0.60 and 0.90. They received naftidrofuryl 200 mg tid or placebo for 12 months. Outcome measures included physiological painfree and maximal walking distances using the PADHOC device. The principle of this device is the measurement of the intermalleolar distances using ultrasound telemetry. The PADHOC measures the walking distance and the speed profile in an ambulatory subject. RESULTS: 182 patients were randomised and 168 entered the intention to treat analysis. The two groups were well matched for demographic variables, risk factors and history of vascular disease. After 12-month treatment, patients who received naftidrofuryl had a 107% improvement of geometric physiological pain-free walking distance versus 12% in the placebo group (P < 0.001) and 74% improvement of geometric maximal physiological walking distance versus 1% in the placebo group (P < 0.001). CONCLUSION: This study demonstrates the efficacy of naftidrofuryl versus placebo in patients with intermittent claudication using a new device measuring the walking distances of the patients in a more physiological way than the treadmill test.
|
Authors | H Boccalon, P Lehert, M Mosnier |
Journal | Annales de cardiologie et d'angeiologie
(Ann Cardiol Angeiol (Paris))
Vol. 50
Issue 3
Pg. 175-82
(Apr 2001)
ISSN: 0003-3928 [Print] France |
Vernacular Title | Effet du naftidrofuryl sur la distance de marche physiologique chez des patients au stade de claudication intermittente. |
PMID | 12555510
(Publication Type: Clinical Trial, English Abstract, Journal Article, Randomized Controlled Trial)
|
Chemical References |
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Female
- Humans
- Intermittent Claudication
(drug therapy, physiopathology)
- Male
- Middle Aged
- Nafronyl
(therapeutic use)
- Walking
(physiology)
|